Literature DB >> 15339846

Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells.

Frank Dicker1, Arnon P Kater, Tetsuya Fukuda, Thomas J Kipps.   

Abstract

Chronic lymphocytic leukemia (CLL) B cells become sensitive to Fas (CD95)-mediated apoptosis 3 to 5 days after CD40 ligation. However, CD4+ cytotoxic T lymphocytes (CTLs) can kill CLL B cells via a Fas-ligand (CD178)-dependent process within 24 hours after CD40 cross-linking, when ligation of CD95 alone is insufficient to induce apoptosis. In addition to CD95, CD40-activated CLL cells also express DR5, a receptor for tumor-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) that is expressed by CD4+ CTL. In addition, CD40 ligation in vitro and in vivo induces CLL cells to express the proapoptotic protein, BH3 interacting domain death agonist (Bid), which can facilitate crosstalk between mitochondrial-dependent, apoptosis-inducing pathways and death receptors, such as death receptor 5 (DR5). To evaluate whether ligation of CD95 and/or DR5 can induce apoptosis of CD40-activated CLL cells, we generated artificial cytotoxic effector cells that express both human TRAIL and CD178 (Chinese hamster ovary [CHO]-CD178/TRAIL) or only TRAIL (CHO-TRAIL) or CD178 (CHO-CD178). CHO-CD178/TRAIL cells were significantly more effective in killing CD40-activated CLL cells than either CHO-TRAIL or CHO-CD178 and, unlike the latter, could kill CLL cells 24 hours after CD40 ligation. We conclude that CD40 ligation induces CLL cells to express the proapoptotic molecule Bid and the death receptors CD95 and DR5, the latter of which can act synergistically to induce caspase-dependent apoptosis of CD40-activated CLL B cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339846     DOI: 10.1182/blood-2003-10-3684

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.

Authors:  Januario E Castro; Johanna Melo-Cardenas; Mauricio Urquiza; Juan S Barajas-Gamboa; Ramin S Pakbaz; Thomas J Kipps
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 2.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

3.  CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.

Authors:  Nicholas F Kuhn; Terence J Purdon; Dayenne G van Leeuwen; Andrea V Lopez; Kevin J Curran; Anthony F Daniyan; Renier J Brentjens
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

4.  A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.

Authors:  W G Wierda; J E Castro; R Aguillon; D Sampath; A Jalayer; J McMannis; C E Prussak; M Keating; T J Kipps
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

5.  CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

Authors:  Frank Dicker; Arnon P Kater; Carlos E Prada; Tetsuya Fukuda; Januario E Castro; Guizhen Sun; Jean Y Wang; Thomas J Kipps
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

6.  Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.

Authors:  Arnon P Kater; Frank Dicker; Massimo Mangiola; Kate Welsh; Richard Houghten; John Ostresh; Adel Nefzi; John C Reed; Clemencia Pinilla; Thomas J Kipps
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

7.  miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL.

Authors:  Valeska Berg; Marion Rusch; Nachiket Vartak; Christian Jüngst; Astrid Schauss; Herbert Waldmann; Christian Hedberg; Christian P Pallasch; Philippe I H Bastiaens; Michael Hallek; Clemens-Martin Wendtner; Lukas P Frenzel
Journal:  Blood       Date:  2015-02-10       Impact factor: 22.113

8.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

9.  Common genetic variants in candidate genes and risk of familial lymphoid malignancies.

Authors:  Xueying Sharon Liang; Neil Caporaso; Mary Lou McMaster; David Ng; Ola Landgren; Meredith Yeager; Stephen Chanock; Lynn R Goldin
Journal:  Br J Haematol       Date:  2009-07-01       Impact factor: 6.998

10.  T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions.

Authors:  Thea M Friedman; Joanne Filicko-O'Hara; Bijoyesh Mookerjee; John L Wagner; Delores A Grosso; Neal Flomenberg; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2007-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.